Comprehensively Covering Multiple Myeloma: IASO Bio's GPRC5D CAR-T Product RD118 Receives IND Approval from NMPA
- Written by PR Newswire
NANJING, China, SHANGHAI and SAN JOSE, Calif., June 28, 2024 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing, and marketing innovative cell therapies and antibody products, today announces that the investigational new drug (IND) application for RD118, an independently...














